{
    "nctId": "NCT02030678",
    "briefTitle": "A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer",
    "officialTitle": "To Evaluate the Clinical Effect of Irinotecan Monotherapy in Treatment of Local Recurrence or Metastatic Breast Cancer Patients Who Accepted at Least 2 Kinds of Chemotherapy Regimens Including Antharcycline or Taxanes.",
    "overallStatus": "UNKNOWN",
    "conditions": "Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 124,
    "primaryOutcomeMeasure": "Disease Control Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Mestatic breast cancer patients whose disease recurrent after using anthracycline or taxane drugs\n\nExclusion Criteria:\n\n* Heart Disease.etc",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}